期刊
CLINICAL GENITOURINARY CANCER
卷 11, 期 2, 页码 175-181出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2012.10.001
关键词
Antiangiogenic therapy; Chemotherapy; Hematologic toxicity; Neoadjuvant; Phase II
资金
- Pfizer Inc, US Medical Oncology, New York, NY
- Pfizer Inc.
- Novartis
- Dendreon
- Celgene
- Merck
- sanofi
- Millennium
- Exelexis
- Bristol-Myers Squibb
- Genetech
- Pfizer
- Cephalon
- Celek
- Hoosier Oncology Group
- Endo Pharmaceuticals
- Bayer
- Medivation
- Tokai
- Glaxo Smith Klein
- Aveo
Parallel trials in advanced disease and neoadjuvant settings are attractive for accelerating drug development in bladder cancer. However, the combination of gemcitabine and cisplatin plus sunitinib was poorly tolerated in both settings, which highlighted the difficulties in combining targeted therapies with cytotoxic agents. Background: Data support chemotherapy combined with antiangiogenic therapy in metastatic urothelial cancer (mUC) and muscle-invasive bladder cancer (MIBC). We investigated the efficacy and safety of gemcitabine, cisplatin, and sunitinib (GCS) in mUC and MIBC in parallel phase II trials. Patients and Methods: Trial 1 enrolled 36 patients with mUC who were chemotherapy naive; trial 2 enrolled 9 patients with MIBC. The primary endpoints for trials 1 and 2 were response rate and pathologic complete response, respectively. GCS was given as first-line treatment for patients with mUC and as neoadjuvant therapy for patients with MIBC. The Simon minimax 2-stage design was used for an objective response rate in trial 1 and for the pathologic complete response rate in trial 2. Results: The initial trial 1 GCS dose was gemcitabine 1000 mg/m(2) intravenously, days 1 and 8; cisplatin 70 mg/m2 intravenously, day 1; and sunitinib 37.5 mg orally daily, days 1 to 14 of a 21-day cycle. These doses proved intolerable. The doses of gemcitabine and cisplatin were subsequently reduced to 800 and 60 mg/m2, respectively, without an improvement in drug delivery, and the trial was closed. This lower-dose regimen was applied in trial 2, which was stopped early due to excess toxicity. Grade 3 to 4 hematologic toxicities occurred in 70% (23/33) of patients in trial 1 and 22% (2/9) of patients in trial 2. In trial 1, the response rate was 49% (95% CI, 31%-67%); in trial 2, the pathologic complete response was 22% (2/9). Due to early closure secondary to toxicity, the sample sizes of both trials were small. Conclusions: Delivery of GCS was hampered by excessive toxicity in both advanced and neoadjuvant settings. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据